Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03358147 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety of PT001 to Placebo and Open-label Spiriva® Respimat® in Subjects With Persistant Asthma
A Phase 2 study, sponsored by Pearl Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 1,077
- Enrollment target
NCT03358147: Completed Phase 2 study, sponsored by Pearl Therapeutics.
NCT03358147 is a Phase 2 study that has completed, run by Pearl Therapeutics. The registered enrollment target is 1,077 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (710% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03358147, a Phase 2 study, has completed, sponsored by Pearl Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 1,077 participants
- Enrollment target
Study Summary
Study Comparing the Efficacy and Safety of PT001 to Placebo and Open-label Spiriva® Respimat® in Subjects With Persistent Asthma
Primary Outcome
Change from baseline in forced expiratory volume in 1 second (FEV1) area under the curve from 0 to 4 hours (AUC0-4)AUC was normalized for length of follow up (e.g. typically 4 hours).
Interventions
- DRUG Placebo MDI
- DRUG GP MDI 28.8 μg
- DRUG GP MDI 14.4 μg
- DRUG GP MDI 7.2 μg
- DRUG Spiriva Respimat 2.5 μg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,077 participants |
| Start Date | 2017-12-13 |
| Est. Completion | 2019-09-12 |
| Phase | Phase 2 |
What the finished NCT03358147 record still lists
NCT03358147 is an interventional study that assigns participants to a tested intervention. Its 1,077 participants enrollment target places it among the larger protocols in the corpus, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (710% higher).
The record links to 0 conditions, and to 5 interventions - of which Placebo MDI is the first listed.
NCT03358147 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03358147 about?
NCT03358147 is a clinical study titled "Efficacy and Safety of PT001 to Placebo and Open-label Spiriva® Respimat® in Subjects With Persistant Asthma". Study Comparing the Efficacy and Safety of PT001 to Placebo and Open-label Spiriva® Respimat® in Subjects With Persistent Asthma
What is the current status of trial NCT03358147?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 1,077 participants. The study started on 2017-12-13. Estimated completion is 2019-09-12.
What interventions are being tested in trial NCT03358147?
The interventions under investigation include: Placebo MDI (DRUG), GP MDI 28.8 μg (DRUG), GP MDI 14.4 μg (DRUG), GP MDI 7.2 μg (DRUG), Spiriva Respimat 2.5 μg (DRUG).
Who is sponsoring clinical trial NCT03358147?
This trial is sponsored by Pearl Therapeutics, which has 31 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03358147's enrollment target sits among peer trials
1,077 23rd of 2000 higher than 1,978 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07084883 · 1,076 participants
Pivotal Trial of an Automated AI-based System for Early Diagnosis and Prediction of Late Age-related Macular Degeneration
- NCT06658808 · 1,075 participants · NA
Efficacy-Implementation Study for PC CARES in Rural Alaska
- NCT06074068 · 1,080 participants · NA
Father-Focused Intervention for Reducing Family Violence and Symptoms in Children
- NCT07213804 · 1,080 participants · Phase 3
A Two-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Part B) Ovarian Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI